Dr. Edward Lin discusses why a combination of what some might call an unlikely pair of drugs that with precise timing can prove effective in waking up sleeping cancer stem cells—giving treatment a better shot at fighting colorectal cancer. Dr. Edward Lin, a medical oncologist at SCCA, an associate professor at the University of Washington, and an associate member of the Fred Hutchinson Cancer Research Center is leading the ADAPT trial and explains what he is hopeful for and how this may change the way we look at the disease.
Share this Video
Related Videos In Colorectal Cancer
Thierry André, ASCO20: Phase III KEYNOTE-177 Trial of Pembrolizumab in Metastatic Colorectal Cancer
touchONCOLOGY were delighted to speak with Dr Thierry André to discuss the interim analysis of the randomised open-label phase III KEYNOTE-177 trial (Clinicaltrials.gov identifier: NCT02563002) comparing the programmed cell death protein antibody pembrolizumab with standard-of-care chemotherapy. The data was presented at the ASCO20 Virtual annual meeting. Questions 1. What are the limitations of the current standard […]
Marc Peeters, ESMO 2018 – Using Biomarkers to Guide Treatment in Colorectal Cancer
In this interview at ESMO 2018, Marc Peeters talks to touchONCOLOGY about colorectal cancer tumour location and biomarkers. He explains that left-sided cancers have a better prognosis and suggests some possible reasons for this. Dr Peeters also discusses how the use of biomarkers has developed in the last 10 years and how treatment and prognosis […]
Rita Laeufle, ESMO 2018 – Patient Selection for Abituzumab in Metastatic Colorectal Cancer
The Poseidon study was a phase I/II study in second-line KRAS mild-type metastatic colorectal cancer (mCRC) that did not meet its endpoint of progression-free survival, but did suggest a subgroup of patients with high alpha v beta 6 integrin expression who would benefit from abituzumab. In this interview, Dr Rita Laeufle tells us about the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!